A study to look at the efficacy of axillary reverse mapping in patients who are planned for upfront surgery.

A study evaluating the efficacy of Axillary Reverse Mapping in biopsy proven patients undergoing upfront surgery - ARM

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/02/023631

Enrollment

100

Registered

2020-02-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Injection of blue dye and/or radiocolloid and indocyanin green: Injection of blue dye and/or radiocolloid in the peritumoral region and indocyanin green in the medial aspect of the arm

Eligibility

Inclusion criteria

Inclusion criteria: Biopsy confirmed early breast cancer with clinical N0/N1 axilla

Exclusion criteria

Exclusion criteria: 1. Matted nodes in the axilla or locally advanced breast cancer 2.Prior surgeries in the upper limb, axilla or breast 3.Prior treatment for breast cancer including neoadjuvant chemotherapy 4.Pregnant woman 5. Allergies to Indocyanine dye or blue dye

Design outcomes

Primary

Measure	Time frame
1. Identification rate and location of the ARM nodesTimepoint: After completion of the study	—

Secondary

Measure	Time frame
1. Histopathological correlation of ARM node and nodes in low axillary sampling 2. Develop an algorithm between ARM nodes and nodes in Anatomical axillary samplingTimepoint: After completion of the study	—

Countries

India

Contacts

Public ContactMs Shabina Siddique

Tata Memorial Centre

vaniparmar@gmail.com02224177000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026